Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer
Despite efforts to promote health policies focused on screening and early detection, cervical cancer continues to be one of the leading causes of mortality in women; in 2020, estimated 30,000 deaths in Latin America were reported for this type of tumor. While the therapies used to treat cervical can...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.773438/full |
| _version_ | 1819121120397230080 |
|---|---|
| author | Carlos Contreras-Romero Eloy-Andrés Pérez-Yépez Eloy-Andrés Pérez-Yépez Antonio Daniel Martinez-Gutierrez Alma Campos-Parra Alejandro Zentella-Dehesa Nadia Jacobo-Herrera César López-Camarillo Guillermo Corredor-Alonso Jaime Martínez-Coronel Mauricio Rodríguez-Dorantes David Cantu de León Carlos Pérez-Plasencia Carlos Pérez-Plasencia |
| author_facet | Carlos Contreras-Romero Eloy-Andrés Pérez-Yépez Eloy-Andrés Pérez-Yépez Antonio Daniel Martinez-Gutierrez Alma Campos-Parra Alejandro Zentella-Dehesa Nadia Jacobo-Herrera César López-Camarillo Guillermo Corredor-Alonso Jaime Martínez-Coronel Mauricio Rodríguez-Dorantes David Cantu de León Carlos Pérez-Plasencia Carlos Pérez-Plasencia |
| author_sort | Carlos Contreras-Romero |
| collection | DOAJ |
| description | Despite efforts to promote health policies focused on screening and early detection, cervical cancer continues to be one of the leading causes of mortality in women; in 2020, estimated 30,000 deaths in Latin America were reported for this type of tumor. While the therapies used to treat cervical cancer have excellent results in tumors identified in early stages, those women who are diagnosed in locally advanced and advanced stages show survival rates at 5 years of <50%. Molecular patterns associated with clinical response have been studied in patients who present resistance to treatment; none of them have reached clinical practice. It is therefore necessary to continue analyzing molecular patterns that allow us to identify patients at risk of developing resistance to conventional therapy. In this study, we analyzed the global methylation profile of 22 patients diagnosed with locally advanced cervical cancer and validated the genomic results in an independent cohort of 70 patients. We showed that BRD9 promoter region methylation and CTU1 demethylation were associated with a higher overall survival (p = 0.06) and progression-free survival (p = 0.0001), whereas DOCK8 demethylation was associated with therapy-resistant patients and a lower overall survival and progression-free survival (p = 0.025 and p = 0.0001, respectively). Our results suggest that methylation of promoter regions in specific genes may provide molecular markers associated with response to treatment in cancer; further investigation is needed. |
| first_indexed | 2024-12-22T06:31:30Z |
| format | Article |
| id | doaj.art-3d41a4c5c2104c9cabea71126bd2c0e0 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T06:31:30Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3d41a4c5c2104c9cabea71126bd2c0e02022-12-21T18:35:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.773438773438Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical CancerCarlos Contreras-Romero0Eloy-Andrés Pérez-Yépez1Eloy-Andrés Pérez-Yépez2Antonio Daniel Martinez-Gutierrez3Alma Campos-Parra4Alejandro Zentella-Dehesa5Nadia Jacobo-Herrera6César López-Camarillo7Guillermo Corredor-Alonso8Jaime Martínez-Coronel9Mauricio Rodríguez-Dorantes10David Cantu de León11Carlos Pérez-Plasencia12Carlos Pérez-Plasencia13Laboratorio de Genómica, Insituto Nacional de Cancerología, Ciudad de México, MexicoLaboratorio de Genómica, Insituto Nacional de Cancerología, Ciudad de México, MexicoCátedra CONACYT, Dirección de cátedras, Consejo Nacional de Ciencia y Tecnología (CONACYT), Mexico City, MexicoLaboratorio de Genómica, Insituto Nacional de Cancerología, Ciudad de México, MexicoLaboratorio de Genómica, Insituto Nacional de Cancerología, Ciudad de México, MexicoPrograma Institucional de Cáncer de Mama, Dpto Medicina Genómica y Toxicología Ambiental, IIB, Universidad Nacional Autónoma de México (UNAM), Mexico City, MexicoUnidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Ciudad de México, MexicoPosgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), Mexico City, MexicoLaboratorio de Patología, Hospital General de Zona #92, Ciudad Acuña, MexicoLaboratorio de Genómica, Insituto Nacional de Cancerología, Ciudad de México, MexicoLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City, MexicoLaboratorio de Genómica, Insituto Nacional de Cancerología, Ciudad de México, MexicoLaboratorio de Genómica, Insituto Nacional de Cancerología, Ciudad de México, MexicoLaboratorio de Genómica, Unidad de Biomedicina, FES-Iztacala, UNAM, Tlalnepantla, MexicoDespite efforts to promote health policies focused on screening and early detection, cervical cancer continues to be one of the leading causes of mortality in women; in 2020, estimated 30,000 deaths in Latin America were reported for this type of tumor. While the therapies used to treat cervical cancer have excellent results in tumors identified in early stages, those women who are diagnosed in locally advanced and advanced stages show survival rates at 5 years of <50%. Molecular patterns associated with clinical response have been studied in patients who present resistance to treatment; none of them have reached clinical practice. It is therefore necessary to continue analyzing molecular patterns that allow us to identify patients at risk of developing resistance to conventional therapy. In this study, we analyzed the global methylation profile of 22 patients diagnosed with locally advanced cervical cancer and validated the genomic results in an independent cohort of 70 patients. We showed that BRD9 promoter region methylation and CTU1 demethylation were associated with a higher overall survival (p = 0.06) and progression-free survival (p = 0.0001), whereas DOCK8 demethylation was associated with therapy-resistant patients and a lower overall survival and progression-free survival (p = 0.025 and p = 0.0001, respectively). Our results suggest that methylation of promoter regions in specific genes may provide molecular markers associated with response to treatment in cancer; further investigation is needed.https://www.frontiersin.org/articles/10.3389/fonc.2022.773438/fullgene promoter methylationchemoradioresistancecervical cancerbiomarkersCisplatin-Radiotherapy sensitivity |
| spellingShingle | Carlos Contreras-Romero Eloy-Andrés Pérez-Yépez Eloy-Andrés Pérez-Yépez Antonio Daniel Martinez-Gutierrez Alma Campos-Parra Alejandro Zentella-Dehesa Nadia Jacobo-Herrera César López-Camarillo Guillermo Corredor-Alonso Jaime Martínez-Coronel Mauricio Rodríguez-Dorantes David Cantu de León Carlos Pérez-Plasencia Carlos Pérez-Plasencia Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer Frontiers in Oncology gene promoter methylation chemoradioresistance cervical cancer biomarkers Cisplatin-Radiotherapy sensitivity |
| title | Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer |
| title_full | Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer |
| title_fullStr | Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer |
| title_full_unstemmed | Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer |
| title_short | Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer |
| title_sort | gene promoter methylation signature as biomarker to predict cisplatin radiotherapy sensitivity in locally advanced cervical cancer |
| topic | gene promoter methylation chemoradioresistance cervical cancer biomarkers Cisplatin-Radiotherapy sensitivity |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.773438/full |
| work_keys_str_mv | AT carloscontrerasromero genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT eloyandresperezyepez genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT eloyandresperezyepez genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT antoniodanielmartinezgutierrez genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT almacamposparra genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT alejandrozentelladehesa genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT nadiajacoboherrera genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT cesarlopezcamarillo genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT guillermocorredoralonso genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT jaimemartinezcoronel genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT mauriciorodriguezdorantes genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT davidcantudeleon genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT carlosperezplasencia genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer AT carlosperezplasencia genepromotermethylationsignatureasbiomarkertopredictcisplatinradiotherapysensitivityinlocallyadvancedcervicalcancer |